ARW ON RNA
Commercializing mRNA: 3 "Action Items" To Turn Promising Science Into Real-World Impact
The recent Alliance for mRNA Medicines’ inaugural Ascent conference provided us with a lot of great updates on the mRNA industry’s progress. But throughout each of these specific conversations, there was a shared underlying question: How can we become a less esoteric industry?
OUR EXPERT NETWORK
-
![DNA RNA editing-GettyImages-1398567874]( "RNase Control: An Overview With Market Trends")
RNase Control: An Overview With Market TrendsThis article shares an overview of ribonuclease (RNase) control and some associated macro market research.
-
![GettyImages-1295693748-mRNA]( "Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases")
Developing Bespoke Antisense Oligonucleotides To Treat Rare DiseasesEveryONE Medicines CEO, Kent Rogers, explains the company’s mission to address a major unmet need in children with rare neurodegenerative diseases, one patient at a time.
-
![Cell transfection with plasmid GettyImages-1290924802]( "Sourcing Plasmid DNA From CDMOs Got More Challenging — Here's Why")
Sourcing Plasmid DNA From CDMOs Got More Challenging — Here's WhyThe demand for plasmid DNA products is intrinsically linked to unique market conditions and funding environments. Here's what's driving them.
-
![Bright Ideas power energy-GettyImages-1454915377]( "CMC Strategies With CDMOs: Ensuring CQAs For Oligos And Peptides")
CMC Strategies With CDMOs: Ensuring CQAs For Oligos And PeptidesDeveloping a practical chemistry, manufacturing, and controls (CMC) strategy for oligonucleotides and peptides demands a shift in approach in terms of the way you collaborate with your CDMO.
-
![protein bio-synthesis GettyImages-1355122387]( "RNA Therapeutics: New Market Research")
RNA Therapeutics: New Market ResearchAccording to our new market research, the RNA therapeutics industry is predicted to exceed $31 billion by 2032. This article shares key findings and trends.
WEBINARS
MEET ARW
I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.
Start the conversation by following me on LinkedIn!
ARW ON BUSINESS OF BIOTECH
-
![24_01_BoB_1280x720_Ep217]( "Pivoting To RNA With Circio's Dr. Erik Digman Wiklund")
This week, it’s another “Business of Biotech-meets-Business-of-RNA” takeover with Circio CEO Erik Digman Wiklund, Ph.D. and guest co-host Anna Rose Welch of Advancing RNA. While Circio’s legacy is in cancer immunology (it still boasts a cancer vaccine candidate targeting KRAS driver mutations), the company made a bold pivot, of sorts, when it committed headlong to the circular RNA future. Now, it’s in the throes of fine-tuning a platform for the development of novel circRNA medicines for rare disease, vaccines, and cancer.
-
![24_01_BoB_1280x720_Ep216]( "mRNA Upstarts With Radar Therapeutics' Sophia Lugo and Eerik Kaseniit, Ph.D.")
Guest co-host Anna Rose Welch of Advancing RNA fame joins us on this week’s Business of Biotech podcast for a conversation with the leaders of RNA upstart Radar Therapeutics. The company’s co-founders, Eerik Kaseniit, Ph.D. (CSO & President) and Sophia Lugo (CEO), are making waves in the mRNA therapeutics space on the heels of the invention of a precision-expressed mRNA technology that laid bare the path to Radar’s inception.
-
![24_01_BoB_1280x720_Ep199]( "Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch")
As if Orna Therapeutics' CEO, Thomas Barnes, isn't enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to biotech, the therapeutic proposition of circular, or "O", RNA and why it holds great potential to best linear RNA constructs, the novel, platform- and partnership-based approaches Orna is taking to address B-cell lymphomas and Duchenne Muscular Dystrophy, viral vector and lipid nanoparticle complexity, and a whole lot more.
VIRTUAL EVENTS
- Achieving Next-Generation mRNA-LNP Therapeutics Delivery
- From Bottleneck To Breakthrough: Reimagining The mRNA Therapeutics Supply Chain
- Can We Do Better? Current & Future Realities of mRNA Process Development
- Opening The "Black Box" Of The mRNA Regulatory Paradigm
- Got Raw Materials? The State Of The mRNA Supply Chain
- mRNA For Cancer Immunotherapy: 2024 Outlook
NEWSLETTER ARCHIVE
- 12.04.24 -- How Platform Technologies Are Shaping The Gene Therapy Landscape
- 11.27.24 -- Tackling Standardization For mRNA Therapeutics
- 11.25.24 -- Oligonucleotide Synthesizers That Take You From Start To Finish
- 11.20.24 -- Tips For Addressing Vaccine Demand – Strategies For C&G And mRNA
- 11.20.24 -- Regulatory Considerations For mRNA Platforms
- 11.13.24 -- Strategies To Address FDA CMC Trends For mRNA Therapies